SANOFI VENTURES

Nucleai Closes $33 Million Series B Financing to Advance Spatial Biology Platform for Drug Research, Development and Diagnostics

Retrieved on: 
Tuesday, March 22, 2022
Data Management, Biotechnology, Technology, Health, Pharmaceutical, Other Science, Research, Software, Nanotechnology, Science, Clinical Trials, Drug development, Biomarker, Section 32, Degenerative disease, Clinical trial, Cros, Vaccine, Decision-making, Pathology, Neoplasm, Probability, Precision medicine, CEO, Intelligence, Laboratory, MD, Artificial intelligence, Technology, Spatial analysis, Drug discovery, Section, Patient, Fine chemical, Medical imaging, Sanofi, SECTION 32, SANOFI VENTURES, NUCLEAI

This Series B financing brings Nucleais overall funding to close to $50 million since the company was founded four years ago.

Key Points: 
  • This Series B financing brings Nucleais overall funding to close to $50 million since the company was founded four years ago.
  • The rapid growth and achievements of the Nucleai team have them well-positioned to be spatial biology platform leaders, transforming current approaches to pathology, said Cris De Luca.
  • Nucleai is working with most of the leading pharmaceutical companies to harness spatial biology for new drug development, clinical trials, and clinical treatment decisions.
  • www.sanofiventures.com
    Nucleai is an AI-powered spatial biology company with a mission to transform drug development and clinical treatment decisions by unlocking the power of pathology data.

Glycomine Closes $68 Million Series B to Advance into Clinical Trials a Novel Treatment for PMM2-CDG, a Rare Glycosylation Disease

Retrieved on: 
Wednesday, June 23, 2021
Professional services, Health, Finance, Clinical trials, Pharmaceutical, Biotechnology, Congenital disorders of glycosylation, PMM2, Genetic genealogy, Medical genetics, Branches of biology, Novo Holdings A/S, CDG, PMM2-CDG, Glycomine, Inc., Abingworth, Sanofi Ventures, RiverVest Venture Partners, Remiges Ventures, PMM2-CDG, GLYCOMINE, INC., ABINGWORTH, SANOFI VENTURES, RIVERVEST VENTURE PARTNERS, REMIGES VENTURES

The proceeds of the financing will be used to advance Glycomines lead drug candidate, GLM101, through initial clinical trials in patients.

Key Points: 
  • The proceeds of the financing will be used to advance Glycomines lead drug candidate, GLM101, through initial clinical trials in patients.
  • GLM101 is a novel substrate replacement therapy in development to treat phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG), a rare disease representing a critical unmet medical need.
  • The Series B financing includes $35 million of new funds in addition to the $33 million announced in August 2019.
  • In addition, all previous Series B investors Novo Holdings A/S, Asahi Kasei Pharma Ventures, Mission BioCapital, Sanderling Ventures, and Chiesi Ventures participated.